Table 4.

Studies of sofosbuvir plus daclatasvir with or without ribavirin in recipients with hepatitis C recurrence after liver transplantation

Authors	No. of patients	Patient characteristics	Antiviral Scheme (duration)	On treatment virological response (%)	SVR (%)
Leroy et al[39], (CUPILT study)	21	FCH: 100%, Treatment experience: 67%	SOF + Daclatasvir ± RBV (n = 13)SOF + RBV (n = 6)(24 wk)	95 (12 wk)	-
Conti et al[40]	55	Fibrosis F3-F4: 33%,FCH: 7%	SOF + Daclatasvir(24 wk)	85 (8 wk)	-

FCH: Fibrosing cholestatic hepatitis.